Published in Expert Opin Med Diagn on November 01, 2009
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer (2010) 1.54
Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics (2011) 1.36
Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem (2010) 1.16
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics (2013) 1.09
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J Proteomics (2012) 0.96
The sweet and sour of serological glycoprotein tumor biomarker quantification. BMC Med (2013) 0.88
At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment. J Gastric Cancer (2014) 0.79
Current and future applications of magnetic resonance imaging (MRI) to breast and ovarian cancer patient management. P R Health Sci J (2010) 0.77
Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma. PLoS One (2015) 0.76
Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls. Exp Hematol Oncol (2013) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
The case for early detection. Nat Rev Cancer (2003) 6.96
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
Screening for ovarian cancer: a pilot randomised controlled trial. Lancet (1999) 5.81
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol (2004) 5.29
Cancer immunology. N Engl J Med (2008) 5.22
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Mining the plasma proteome for cancer biomarkers. Nature (2008) 4.10
Screening for prostate cancer--the controversy that refuses to die. N Engl J Med (2009) 3.59
American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin (2006) 3.46
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem (2001) 2.85
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology (2000) 2.26
Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A (2007) 2.22
Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol (2001) 2.06
Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology (2000) 1.95
Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med (1993) 1.89
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol (2008) 1.78
Early detection of ovarian cancer. Dis Markers (2007) 1.77
Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res (1975) 1.75
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Prostate-specific antigen: current status. CA Cancer J Clin (2001) 1.63
Age-specific reference ranges for serum PSA. N Engl J Med (1996) 1.61
Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res (2007) 1.56
Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int J Cancer (1968) 1.53
AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta (2001) 1.51
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
Screening tests for hepatocellular carcinoma. Clin Liver Dis (2005) 1.47
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer (1994) 1.46
Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology (1984) 1.41
Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology (2007) 1.36
PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am (1993) 1.33
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer (2005) 1.26
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol (1996) 1.16
Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol (1999) 1.14
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology (1996) 1.12
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med (2008) 1.12
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate (1995) 1.11
Cancer proteomics: in pursuit of "true" biomarker discovery. Cancer Epidemiol Biomarkers Prev (2005) 1.06
MAPU: Max-Planck Unified database of organellar, cellular, tissue and body fluid proteomes. Nucleic Acids Res (2006) 1.06
Cancer biomarker discovery in plasma using a tissue-targeted proteomic approach. Cancer Epidemiol Biomarkers Prev (2007) 1.05
Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology (1996) 1.00
Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics (2007) 0.99
Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. Am J Surg (1986) 0.98
Prostate-specific antigen. Its discovery and biochemical characteristics. Urol Clin North Am (1997) 0.94
Screening for cancer in viral hepatitis. Clin Liver Dis (2001) 0.93
Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma. Oncol Rep (1999) 0.89
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther (2005) 0.87
Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology (1995) 0.87
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology (1997) 0.86
Prostate-specific antigen: update 1997. J Int Fed Clin Chem (1997) 0.83
Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. J Urol (1998) 0.80
Identity of PSA purified from seminal fluid by different methods: comparison by amino acid analysis and assigned extinction coefficients. Prostate (1995) 0.79
Redesigned proficiency testing materials improve survey outcomes for prostate-specific antigen. A College of American Pathologists Ligand Assay Survey tool. Arch Pathol Lab Med (2000) 0.79
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol (1997) 0.79
Automatic and simultaneous analysis of Lens culinaris agglutinin-reactive alpha-fetoprotein ratio and total alpha-fetoprotein concentration. Anal Chem (1998) 0.78
Prostate cancer: is PSA velocity useful? Nat Rev Urol (2009) 0.78
Affinity chromatographic separation of alpha-fetoprotein variants: development of a mini-column procedure, and application to cancer patients. Clin Chem (1986) 0.77
Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics? Clin Chem Lab Med (2008) 0.76
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 4.42
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clin Chem (2009) 2.01
Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res (2006) 1.93
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Proteomics: a new diagnostic frontier. Clin Chem (2006) 1.82
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med (2002) 1.72
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res (2004) 1.63
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate (2003) 1.60
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg (2003) 1.54
Retracted Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res (2008) 1.51
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem (2006) 1.45
Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem (2003) 1.45
Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics (2011) 1.36
Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer (2005) 1.35
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res (2009) 1.30
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol (2003) 1.30
Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell (2012) 1.28
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res (2009) 1.26
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev (2010) 1.25
Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res (2005) 1.23
Biomarkers in prostate cancer: what's new? Curr Opin Oncol (2014) 1.16
Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem (2010) 1.16
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. Anal Chem (2011) 1.15
The clinical application of proteomics. Clin Chim Acta (2005) 1.13
HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res (2003) 1.13
Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol (2008) 1.12
Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol (2006) 1.11
Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate (2008) 1.10
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics (2013) 1.09
Updating risk prediction tools: a case study in prostate cancer. Biom J (2011) 1.08
Cancer proteomics: in pursuit of "true" biomarker discovery. Cancer Epidemiol Biomarkers Prev (2005) 1.06
Cancer biomarker discovery in plasma using a tissue-targeted proteomic approach. Cancer Epidemiol Biomarkers Prev (2007) 1.05
Analytic bias of thyroid function tests: analysis of a College of American Pathologists fresh frozen serum pool by 3900 clinical laboratories. Arch Pathol Lab Med (2005) 1.04
Retracted Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res (2007) 1.03
Multicentre performance evaluation of the E170 module for modular analytics. Clin Chem Lab Med (2004) 1.03
Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol (2005) 1.03
A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med (2011) 1.03
Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J Proteome Res (2012) 1.01
Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer. J Exp Ther Oncol (2004) 1.00
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol (2012) 1.00
MODULAR ANALYTICS: A New Approach to Automation in the Clinical Laboratory. J Autom Methods Manag Chem (2005) 1.00
Cancer proteomics: Serum diagnostics for tumor marker discovery. Ann N Y Acad Sci (2004) 1.00
Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res (2005) 1.00
The human proteome - a scientific opportunity for transforming diagnostics, therapeutics, and healthcare. Clin Proteomics (2012) 0.98
Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta (2012) 0.98
The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol (2009) 0.97
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J Proteomics (2012) 0.96
Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol (2012) 0.94
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia (2009) 0.94
Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res (2007) 0.94
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology (2004) 0.94
Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles). Mol Cell Proteomics (2011) 0.94
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. J Proteome Res (2013) 0.94
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem (2011) 0.94
Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance. Proteomics Clin Appl (2009) 0.93
Analytical performance of 4 automated assays for measurement of cystatin C. Clin Chem (2010) 0.93